iShares Nasdaq Biotech Index (IBB) $78.27 +3.18%

| April 1, 2008 More

Biotech stocks have benefited from the recent decline in risk perceptions. The iShares Biotech Fund (IBB) is up 3.6 percent today and has added 8 percent since March 20, compared to a 2.9 percent gain for the S&P 500 (.SPX). Today, a number of individual biotech names saw unusual volume in the options market. The list includes Intermune (ITMN), Pozen Pharmaceuticals (POZN), Amylin Pharmaceuticals (AMLN), OSI Pharmaceuticals (OSIP), and Forest Labs (FRX).

Category: All ETFs

Please share if others would benefit

Comments are closed.

About the Author (Author Profile)

Frederic Ruffy is a well-known trader, writer, and strategist who has spent years educating investors and creating intelligent, insightful, unbiased market observations that are frequently cited by the Wall Street Journal and other financial publications. As senior analyst, Fred provides frequent and regular notes and daily updates for activity of interest.

«
»
s2Member®